- Home
- OLMA vs JRI Comparison
OLMA vs JRI Comparison
Compare OLMA & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- JRI
- Stock Information
- Founded
- OLMA 2006
- JRI 2012
- Country
- OLMA United States
- JRI United States
- Employees
- OLMA N/A
- JRI N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- JRI Finance Companies
- Sector
- OLMA Health Care
- JRI Finance
- Exchange
- OLMA Nasdaq
- JRI Nasdaq
- Market Cap
- OLMA 299.7M
- JRI 358.6M
- IPO Year
- OLMA 2020
- JRI N/A
- Fundamental
- Price
- OLMA $4.20
- JRI $13.06
- Analyst Decision
- OLMA Strong Buy
- JRI
- Analyst Count
- OLMA 4
- JRI 0
- Target Price
- OLMA $24.50
- JRI N/A
- AVG Volume (30 Days)
- OLMA 868.7K
- JRI 68.0K
- Earning Date
- OLMA 08-05-2025
- JRI 01-01-0001
- Dividend Yield
- OLMA N/A
- JRI 9.38%
- EPS Growth
- OLMA N/A
- JRI N/A
- EPS
- OLMA N/A
- JRI N/A
- Revenue
- OLMA N/A
- JRI N/A
- Revenue This Year
- OLMA N/A
- JRI N/A
- Revenue Next Year
- OLMA N/A
- JRI N/A
- P/E Ratio
- OLMA N/A
- JRI N/A
- Revenue Growth
- OLMA N/A
- JRI N/A
- 52 Week Low
- OLMA $2.86
- JRI $9.70
- 52 Week High
- OLMA $16.62
- JRI $12.12
- Technical
- Relative Strength Index (RSI)
- OLMA 43.60
- JRI 57.01
- Support Level
- OLMA $3.90
- JRI $12.91
- Resistance Level
- OLMA $4.29
- JRI $13.14
- Average True Range (ATR)
- OLMA 0.36
- JRI 0.11
- MACD
- OLMA -0.03
- JRI -0.00
- Stochastic Oscillator
- OLMA 19.18
- JRI 67.65
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its strategy involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.